NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Curis, Inc. CRIS
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$9.4M
▼ 13.4% vs FY2024
EPS · FY25
$-0.58
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-80.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 9.4M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 80 cents on every revenue dollar this year.
Per share
USD -0.58
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-60.5%
Net margin-80.3%
Return on assets-24.8%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−2.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.4%
−2.7%
+1.8%
−3.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+83.0%
Change, 10 years—
The share count grew 83% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 20.0M
total assets, end of FY2025
Total assetsUSD 20.0M
EquityUSD 5.5M
CashUSD 5.1M
Gross debtUSD 0.00
Net debtUSD -5.1M
Current ratio0.49×
The company holds more cash than debt.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
·
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.58
−6.88
−8.96
−12.14
−0.50
−0.61
−0.97
−0.98
−1.79
−0.45
−0.48
−0.22
−0.15
−0.21
−0.13
−0.06
−0.15
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
−634.7
−143.2
−82.6
−41.0
−61.8
·
−334.2
−199.5
−128.6
−125.1
−50.0
−31.0
−44.3
−23.1
−11.3
−29.7
Shares out B
0.01
0.01
0.01
0.00
0.09
0.09
0.03
0.03
0.03
0.14
0.13
0.09
0.09
0.08
0.08
0.08
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed